BDNF variability in opioid addicts and response to methadone treatment: preliminary findings

Size: px
Start display at page:

Download "BDNF variability in opioid addicts and response to methadone treatment: preliminary findings"

Transcription

1 Genes, Brain and Behavior (2008) 7: # 2008 The Authors Journal compilation # 2008 Blackwell Publishing Ltd BDNF variability in opioid addicts and response to methadone treatment: preliminary findings R. de Cid,,1, F. Fonseca,1, M. Gratacòs, F. Gutierrez, R. Martín-Santos**, X. Estivill,,, * and M. Torrens, **,, * Genes and Disease Program, Center for Genomic Regulation (CRG) and CIBER EpidemiologíaySaludPública (CIBERESP), Barcelona, Spain, National Center of Genotyping (CeGen), Center for Genomic Regulation, Barcelona, Spain, Drug Addiction Unit, IAPS, Barcelona, Spain, Psychology Service, Neuroscience Institute, Hospital Clinic, Barcelona, Spain, **Pharmacology Unit, Institut Municipal d Investigació Mèdica (IMIM), Barcelona, Spain, Psychiatry and Legal Medecine Department, Universitat Autònoma de Barcelona, Barcelona, Spain, and Experimental and Health Sciences Department, Pompeu Fabra University, Barcelona, Spain *Corresponding author: X. Estivill, PRBB Building, Placxa Charles Darwin s/n (Dr. Aiguader 88), Barcelona, Catalonia, Spain. and M. Torrens, IAPs-Hospital del Mar, Passeig Marítim 25-29, Barcelona, Catalonia, Spain. 1 These authors contributed equally to this work. Brain-derived neurotrophic factor (BDNF) signaling pathways have been shown to be essential for opioid-induced plasticity. We conducted an exploratory study to evaluate BDNF variability in opioid addict responders and nonresponders to methadone maintenance treatment (MMT). We analyzed 21 single nucleotide polymorphisms (SNPs) across the BDNF genomic region. Responders and nonresponders were classified by means of illicit opioid consumption detected in random urinalysis. Patients were assessed by a structured interview (Psychiatric Research Interview for Substance and Mental Disorders (PRISM)-DSM-IV) and personality was evaluated by the Cloninger s Temperament and Character Inventory. No clinical, environmental and treatment characteristics were different between the groups, except for the Cooperativeness dimension (P < 0.001). Haplotype block analysis showed a low-frequency (2.7%) haplotype (13 SNPs) in block 1, which was more frequent in the nonresponder group than in the responder group (4/42 vs. 1/135; P corrected ). Fine mapping in block 1 allows us to identify a haplotype subset formed by only six SNPs (rs , rs , rs , rs988748, rs and rs ) associated with differential response to MMT (global P sim ). Carriers of the CCGCCG haplotype had an increased risk of poorer response, even after adjusting for Cooperativeness score (OR % CI , P ). These preliminary results might suggest the involvement of BDNF as a factor to be taken into account in the response to MMT independently of personality traits, environmental cues, methadone dosage and psychiatric comorbidity. Keywords: ASI, BDNF, methadone, opioid dependence, pharmacogenetics, PRISM, substance abuse, TCI Received 17 September 2007, revised 14 December 2007, accepted for publication 16 December 2007 Opioid dependence disorder is a complex disease. The development of a drug addiction and the tendency to relapse are caused by a combination of both genetic and environmental factors (Kreek et al. 2005). Methadone maintenance treatment (MMT) is the most widely used treatment for opioid dependence and has been shown to be effective in opioid-dependent subjects who stay in treatment (Amato et al. 2005). If retention in treatment and/or illicit opioid use is considered as the main treatment outcomes, between 30% and 80% of treated patients respond poorly to MMT (GAO 1990). The provision of adequate doses of methadone and other psychosocial services are the main factors related to the success of MMT (Amato et al. 2005; Ward et al. 1999). Personality characteristics of patients have also been related to MMT outcomes (Cacciola et al. 2001). From the dimensional approach, Cloninger s model posits that personality encompasses partially inherited temperamental traits and acquired character traits (Cloninger et al. 1993). Temperamental dimensions may be correlated to specific brain systems and have been described as genetically independent from each other (Ebstein 2006; Gerra et al. 2005). In recent years, the study of the therapeutic response to MMT according to patients genetic backgrounds has become an issue of increasing interest (Barratt et al. 2006; Crettol et al. 2006; Lawford et al. 2000). Neurotrophins in the brain enhance the growth and maintenance of several neuronal systems, modulate neurotransmission and play a role in plasticity mechanisms such as long-term potentiation (Chao 2003). As a member of the nerve growth factor-related family of neurotrophins, we focused on brain-derived neurotrophic factor (BDNF) (Anderson et al. 1995; Thoenen 1995). Human BDNF is located on chromosome 11p14.1 and encodes a 247 amino acid (aa) preprotein that is proteolytically cleaved to form the 120 aa mature protein, which is 100% conserved between mice, rats, pigs and humans (Maisonpierre et al. 1991). Linkage and association studies with markers in the BDNF genomic region have been associated with personality traits (Lang et al. 2004, 2005) and some diseases, including Parkinson s disease, schizophrenia, bipolar disorder, obsessive-compulsive disorder doi: /j X x 515

2 de Cid et al. and eating disorders. Most studies have focused on a single polymorphism in the pre-domain of BDNF (Val66Met) (Gratacos et al. 2007a). There is also strong evidence showing that the Met66 allele of this functional Val66Met polymorphism is associated with substance abuse (Beuten et al. 2005; Itoh et al. 2005; Matsushita et al. 2004) and specifically with opioid addiction (Cheng et al. 2005). We present the preliminary results of an exploratory study aimed to explore the role of genetic variability of BDNF in response to MMT among a cohort of opioid-addicted subjects. Patients and methods Patients The study recruited participants who met criteria for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) opioid dependence from the MMT Program at a drug abuse outpatient center in Barcelona (CAS Barceloneta). The characteristics of the MMT provided were as follows: no upper limit on methadone dosages prescribed, no restriction on duration of treatment, forced discharge occurring only as a result of patients violent behavior or drug trafficking and clinical management that includes individual counseling and encouraged drug abstinence. To be eligible for the study, patients had to be Caucasian, enrolled in MMT for at least 6 months and receiving a stable methadone dose for the last 2 months. Exclusion criteria were language-related barriers, severe cognitive impairment or any medical disorder that would interfere with the research assessments. Clinical assessment A close-ended questionnaire was used to record patients sociodemographic characteristics, serological status (human immunodeficiency virus, hepatitis C virus (HCV), history of substance use and previous psychiatric treatment. Substance and nonsubstance use psychiatric disorders were diagnosed according to DSM-IV criteria, using the Spanish version of the Psychiatric Research Interview for Substance and Mental Disorders IV (PRISM-IV) in axis I and II (borderline and antisocial personality disorders) (Hasin et al. 2006; Torrens et al. 2004). The degree of addiction-related impairment was assessed using the Spanish version of the Addiction Severity Index (ASI) (Gonzalez et al. 2002; McLellan et al. 1980). Personality characteristics were evaluated using the Spanish version of the self-administered Cloninger s Temperament and Character Inventory (TCI) (Gutierrez et al. 2001). The temperament dimensions included Novelty Seeking, Harm Avoidance, Reward Dependence and Persistence, and the character dimensions included: Self-Directedness, Cooperativeness and Self-Transcendence. Urinalysis to detect heroin use was performed at the center randomly every 1 or 2 weeks, under the supervision of the nursing staff. Procedure According to urinalyses, patients were classified as responders or nonresponders to MMT. Responders to MMT were those patients whose last four urinalysis tests were negative for illicit opioids, and nonresponders were those with two or more of their last four urinalysis tests positive for illicit opioids. Written informed consent was obtained from each subject after they had received a complete description of the study and been given the chance to discuss any questions or issues. The study was approved by the ethical and clinical research committee of the institution. Single nucleotide polymorphisms selection and genotyping Genetic variability in the BDNF genomic region (GenBank accession number NC_000011) was assessed by selecting single nucleotide polymorphisms (SNPs) in a 63.8 kb region including complete coding sequence, 3 0 untranslated region (UTR) and 5 0 UTR regions. SNPs were selected from available databases at the time of experimental design (NCBI database, dbsnp 120; and from Celera databases (http://www.celera.com). A main criterion for inclusion markers was the availability of validation data and uniform distribution of SNPs along BDNF reference sequence. Based on the NCBI database (NCBI Build 36.1;http://www.ncbi.nlm.nih.gov), the common complete coding region and most of the 3 0 UTR region, common for preprotein isoforms a, b and c, are covered, as well the 5 0 UTR region for most of the described transcripts (Table 1). Blood samples were collected from all subjects and genomic DNA was obtained from peripheral blood using standard procedures. SNPs were genotyped using the SNPlexä platform (Applied Biosystems, Foster City, CA, USA) according to the manufacturer s instructions and analyzed on an Applied Biosystems 3730xl DNA Analyzer. Allele calling was performed by clustering analysis using GENEMAPPER v.4.0 software. The genotype call rate was >95%. Genotyping quality was controlled in two ways. First, internal positive and negative controls provided by the manufacturer ABI (Applied Biosystems) were included in the reaction plates. Second, six duplicated samples of two HapMap reference trios were incorporated in the genotyping process. Both genotype concordance and correct Mendelian inheritance were verified. Statistical analysis Differences in sociodemographic and clinical characteristics between groups were examined using chi-squared and one-way analysis of variance tests, with Bonferroni post hoc analysis, using the SPSS software analysis package version TCI scales values were converted into T scores (Population Norms in Cloninger et al. 1994). Genotyped SNPs with a call rate of fewer than 80% were not considered for the association analysis. We tested each polymorphism in the whole group to ensure the fit with Hardy Weinberg equilibrium (HWE). Because of multiple testing, we used a threshold of P ¼ Multivariate logistic regression was used to assess the genetic effect of the SNPs. To better determine the real effect of SNPs on MMT outcome, we first performed a logistic regression analysis including the following variables: sex, age, TCI scores, psychiatric comorbidity and methadone dosage; factors that have aprioriahigh probability to be related to MMT response. Using a stepwise procedure, we selected the statistically significant variables that were included in the final model as covariates. Intergroup comparisons of genotype frequency differences were performed by regression analysis for dominant, recessive, overdominant and log-additive models of inheritance. Unadjusted crude odds ratios (OR) and 95% confidence intervals (95% CI) were calculated. We then calculated the OR adjusted for the clinical variables that were selected in the stepwise logistic regression procedure. The best genetic model was selected using the Akaike s information criteria. Analysis was carried out using the SNPassoc R library, from the Comprehensive R Archive Network. As a high correlation exists between the assayed markers because of tight linkage disequilibrium in the region, the problem of multiple testing was solved using the Spectral Decomposition approach (Li & Ji 2005). Allelewise experiment-wide significance threshold to control type I error rate at 5% resulted in a P value of An additional correction factor was introduced to account for the four inheritance models tested (dominant, recessive, overdominant and log-additive models of inheritance) in the genotype analysis. Haplotype association analysis was performed using a two-step method; first, we used a structured approach to test for association based on block structure and then we performed fine mapping of specific haplotype subsets inside the block using a sliding window approach. All SNPs with a minor allele frequency (MAF) >0.001 and inferred haplotypes with frequencies higher than 1% were included to define the haploblock structure. The block definition was based on the Linkage Disequilibrium (LD) measure D 0 confidence interval block partition algorithm (Gabriel et al. 2002). Haplotype association analysis, as implemented in HAPLOVIEW v.4.0 software (Barrett et al. 2005), was based on block structure definition and the P value was based on simulation procedures derived after simulation steps. A P value of <0.05 was considered statistically significant. 516 Genes, Brain and Behavior (2008) 7:

3 BDNF SNPs in opioid addiction Table 1: Description of SNP markers genotyped in the BDNF genomic region SNP SNP code Reference ID Chromosome position Gene position Transcript position Protein position Alleles MAF HWE* Missing (%) 1 rs rs Exon IX 3 0 UTR C/T rs rs Exon IX 3 0 UTR C/A rs rs Exon IX Coding Ala150Ala G rs6265 rs Exon IX Coding Met66Val G/A rs rs Exon IX 5 0 UTR A hcv rs Intron VIIIh /promoter IX Intronic C/T 0.5 ND 0 7 rs rs Intron VIIIh /promoter IX Intronic C/G rs rs Intron VII Intronic A/G hcv NA Intron VII Intronic T rs rs Intron VII Intronic G/C 1.5 ND 0 11 rs rs Intron VII Intronic G/C hcv rs Intron VII Intronic A/C rs rs Intron VII Intronic G/A rs rs Intron VII Intronic G rs rs Intron VII Intronic T/C rs rs Intron VII Intronic C/G rs rs Intron VII Intronic A/G hcv rs Intron VII Intronic G hcv NA Intron VII Intronic A hcv NA Intron VII Intronic T/A rs rs Intron VII Intronic C/T rs rs Intron VII Intronic C rs rs Exon IV 5 0 UTR G rs rs Intron III Intronic C/G rs rs Intron III Intronic C/T rs rs Intron III Intronic A/G rs rs Intron III Intronic A rs rs Intron III Intronic A/G rs rs Intron III Intronic A/G rs rs Intron III Intronic C/T ND, no Reference ID exists in NCBI; NA, no data because of lack of rare homozygote; MAF, Minor Allele Frequency. Chromosome position is referred to NCBI build Gene position is refereed to exon intron structure boundaries reported in Pruunsild et al. (2007). Transcript position is referred to all different transcripts described for BDNF; NCBI build *HWE was calculated in all group, with a threshold P value of <0.001 accounting for multiple testing of 21 polymorphic SNPs. The sliding window approach was undertaken to better define specific haplotype subsets inside the block. In order to provide a comprehensive assessment of the haplotype subsets within the gene, the size of the window varied from 3, 6 and 10 SNPs. Only haplotypes with frequencies higher than 1% were considered. Global significance of the associated haplotype was estimated using a permutation test implemented in the HAPLO.STATS v package (Lake et al. 2003). A P value based on simulation procedures was derived (P global simulation) and a P value of <0.05 was considered to be statistically significant. Crude and estimated OR and 95% CI for associated haplotypes were calculated using the function HAPLO.GLM implemented in HAPLO.- STATS v in the R programming language (Lake et al. 2003). Results Sociodemographic and clinical characteristics of subjects The clinical sample included 91 patients [66 (73%) male, age range years, mean age 38 8 years]. A total of 68 patients were classified as responders (49 males, mean age 38 7 years) and 23 patients as nonresponders (17 males, mean age 37 9 years). There were no differences between responder and nonresponder groups in terms of prescribed daily methadone dosage ( vs mg/day, t ¼ 1.014, df ¼ 88, P ¼ 0.313) and length of time in MMT (40 43 vs months, t ¼ 1.057, df ¼ 88, P ¼ 0.293). The main sociodemographic, medical and psychopathological characteristics of patients are summarized in Table 2. No differences in the proportions of responders and nonresponders in terms of lifetime and current prevalence of other substance use dependence disorders (cocaine, cannabis, alcohol, sedatives and stimulants) and lifetime psychiatric comorbidity in axes I and II (75% in responders vs. 65% in nonresponders, w 2 ¼ 0.456, df ¼ 1, P ¼ 0.424) were found. Regarding the severity of addiction, there was a tendency in the Other Substance Use dimension Genes, Brain and Behavior (2008) 7:

4 de Cid et al. Table 2: Mean characteristics of study groups Responders (n ¼ 68) Nonresponders (n ¼ 23) P* Male (%) 49 (72) 17 (74) Age in years, mean (SD) 38 (7) 37 (9) Years at school, mean (SD) 9 (2) 9 (4) Single (%) 32 (48) 10 (44) Legal background (%) 38 (57) 11 (52) Live with family (%) 48 (72) 16 (76) Offspring, mean (SD) 0.9 (1.1) 0.8 (1.0) Employed (%) 19 (28) 10 (48) Human immunodeficiency virus þ (%) 25 (37) 5 (22) HCV þ (%) 49 (73) 15 (65) Illicit opioid consumption in months, mean (SD) 148 (86) 89 (56) <0.001 Other substances dependence disorder lifetime prevalence (%) Alcohol 19 (29) 6 (26) Sedatives 17 (26) 7 (30) Stimulants 3 (5) 1 (4) Cannabis 13 (20) 3 (13) Cocaine 44 (67) 12 (52) Days of heroin consumption in the last 30 days, mean (SD) 0.4 (1.26) 10.0 (11.8) <0.001 Days of cocaine consumption in the last 30 days, mean (SD) 1.7 (5.0) 8.5 (11.) Psychiatric comorbidity (lifetime prevalence) (%) 50 (75) 15 (65) Months in MMT, mean (SD) 40 (43) 29 (41) Methadone dosage, mean (SD) (70.96) (49.86) ASI scores, mean (SD) General health status 3.1 (2.3) 3.3 (2.3) Working problems 4.3 (2.8) 3.3 (2.8) Alcohol use 1.3 (1.7) 1.4 (1.4) Substance use 4.9 (2.5) 6.6 (1.8) Legal problems 1.4 (2.0) 2.0 (2.4) Social relationships 3.3 (2.5) 3.0 (2.1) Psychological status 3.0 (2.5) 2.3 (1.9) TCI temperament scales, mean (SD) Harm Avoidance 59.1 (9.9) 56.2 (7.9) Novelty Seeking 52.6 (7.9) 55.0 (9.6) Reward Dependence 45.0 (9.6) 47.1 (7.7) Persistence 42.5 (8.8) 43.9 (9.8) TCI character scales, mean (SD) Self-Directness 41.3 (12.0) 45.3 (8.3) Cooperativeness 41.4 (8.6) 47.4 (5.1) <0.001 Self-Transcendence 41.6 (10.3) 40.7 (8.2) SD, standard deviation. *Values in bold represent significant P values, after Bonferroni correction. of the ASI for the nonresponder group to score higher. However, when substance use in the last 30 days was compared for responders and nonresponders, the only difference found was that as expected, nonresponders reported more days of heroin consumption in last 30 days. The mean number of days of cocaine use during the last 30 days was not significantly different between both groups (Table 2). There was a significant difference in TCI scores between groups only in the Cooperativeness dimension, with the nonresponder group scoring higher (Table 2). Block structure of the BDNF region A detailed description of assayed SNPs is summarized in Table 1. All selected SNPs were in HWE (P > 0.01). Nine out of 30 SNPs were not polymorphic and were not informative to block structure definition. Twenty-one SNPs were used for infer block structure. Extended LD defined one block over the entire genomic region in the whole patient sample. Block structure was then independently derived separately in both patient samples: responders (n ¼ 68) and nonresponders (n ¼ 23). The block definition was slightly different between both groups (Fig. 1). Two blocks were defined in the 518 Genes, Brain and Behavior (2008) 7:

5 BDNF SNPs in opioid addiction Figure 1: Haploblock structure obtained from genotyped SNPs was determined and visualized using the genetic analysis program HAPLO- VIEW. (http://www.broad.mit.edu/mpg/ haploview). The transcripts structure is shown at the top. The lower part of the figure shows the LD block identified using HAPLOVIEW. Representation of the extension of the identified haplotypes are depicted as solid red bars under the transcripts map, and upper the block diagram. All genotyped SNPs are represented: Linkage disequilibrium is calculated by D 0, and each square represents a pairwise value of D 0 with the standard color coding represented in a GOLD heatmap diagram. Stronger LD is represented by red and weaker by blue as indicated in the color key. The boxes in black indicate block structure for responder and nonresponder groups, respectively. Depicted haploblocks were inferred including all SNPs and haplotypes with a frequency >1% using the D 0 confidence interval algorithm. The block structure was slightly different between groups. One block was defined in the responder group, but two blocks were present in the nonresponder group. *SNP 4 (rs6265) corresponds to Val66Met BDNF variant. nonresponder group (47 and 1 kb) and only one in the responder group (57 kb). In the nonresponder group, the major block was conserved in the coding and 3 0 UTR region but was broken upstream of the 5 0 UTR region of transcript NM_170733, which codes for BDNF isoform. Detailed composition of haploblocks for each group is summarized in Fig. 1. BDNF variability between responders and nonresponders to MMT Multivariate logistic regression analysis was performed to identify confounding variables in a predictive model of response to MMT. We included TCI dimension scores, psychiatric comorbidity (in the last 12 months), methadone dosage, age and gender as independent variables in the model. After a stepwise procedure, only Cooperativeness scores remained significant in the model, as also found in the univariate analysis. The genotype distribution in responders and nonresponders under different models of genetic action did not yield statistically significant differences in the crude analysis (P > 0.05) and only was nominal for rs after adjusted analysis for Cooperativeness, P uncorrected ¼ Haplotype analysis revealed a low-frequency haplotype (2.7%) in block 1 associated with a poorer response to MMT (Table 3). AGCTGATCCCGAA haplotype (hcv , Genes, Brain and Behavior (2008) 7:

6 de Cid et al. Table 3: Haplotype block analysis showed a low-frequency haplotype associated with nonresponse to MMT. Haplotype in block 1 was formed by SNPs: hcv , rs , hcv , hcv , rs , rs , hcv , rs , rs988748, rs , rs , rs and rs Haplotype* Frequency Nonresponders Responders P value P value_ AGCTGATCCCGAA /42 1/ AGCTGATCCTAGG /41 34/ AGCTCGTTCCGAA /46 5.2/ AGCTGGTCCTAGG /43 4/ AGATCGTTCCGAA / / GCCCGGATGTGGG / / GGCCGGATGTGGG /44.8 3/ P value_10 000; corrected P value after step permutation procedure as implemented in HAPLOVIEW. *Infered haplotype in block 1 defined by confidence interval block partition algorithm. Bold letters represent informative haplotype tag SNPs (htsnps). Fractional likelihoods of each individual for each haplotype. rs , hcv , hcv , rs , rs , hcv , rs , rs988748, rs , rs , rs and rs ) in block 1 was more frequent in the nonresponder group than in the responder group (4/42 vs. 1/135, P corrected ¼ 0.023). In addition, we observed a haplotype more frequent in responders than in nonresponders (34/102 vs. 5/41, P uncorrected ¼ ), but this result was no longer significant after the permutation validation procedure. The sliding window approach identified a haplotype subset associated with a differential response to MMT, in the 10 and 6 window analyses. The smaller multimarker with statistical significance was the haplotype formed by six SNPs (rs , rs , rs , rs988748, rs and rs ). This haplotype was significantly associated with a differential response (global P sim ¼ 0.011). Haplotype analysis showed that carriers of the CCGCCG haplotype (both homozygotes and heterozygotes) had an increased risk of poorer response (OR ¼ 11.99, 95% CI , P ¼ 0.032), even after adjusting for Cooperativeness, although in this case, a wider CI was obtained (OR ¼ 20.25, 95% CI ), P ¼ 0.025). Discussion This exploratory analysis suggests that BDNF variability confers a differential susceptibility to MMT response in opioid-dependent patients. Although association of BDNF with opioid dependence disorder has been previously reported (Cheng et al. 2005), as far as we are aware, this is the first time that BDNF variability has been linked to opioid therapeutic response. The relevance of BDNF variability to therapeutic response has been previously suggested with regard to the efficacy of other psychiatric treatments such as prophylaxis with lithium carbonate for bipolar mood disorders (Rybakowski et al. 2005) and antidepressants for unipolar depression (Gratacos et al. 2007b). Sociodemographics, medical status and psychiatric comorbidity were not associated with a differential response to MMT, as reported by others (Kellogg et al. 2006). Psychiatric disorders such as mood disorders, anxiety disorders, eating disorders and schizophrenia have been associated with both opioid dependence disorder (Brooner et al. 1997) and BDNF variability (Gratacos et al. 2007a). However, our results suggest that the effect of BDNF on MMT response is independent of the presence of psychiatric comorbidity. Similar to pharmacological treatment studies on eating disorders (Klump et al. 2004), lower Cooperativeness scores were observed in responder group. However, other studies on major depression and panic disorder showed opposite results (Hirano et al. 2002; Marchesi et al. 2006). Although a sample size bias cannot be discarded, these differences could be diagnosis specific or might be related to the TCI assessment time (Marchesi et al. 2006). Genetic variability in BDNF plays a role in patients undergoing MMT, as demonstrated by our findings. From the adjusted analysis, we identified one haplotype with a low frequency that confers a poorer response in patients undergoing MMT. Nevertheless, given the low frequency of this haplotype, it seems clear that no single effect is present and that other factors should be considered. Because BDNF has been linked to both the dopaminergic system (Seroogy et al. 1994) and the noradrenergic system (Akbarian et al. 2002) that play a relevant role in opioid dependence disorder, it is not unlikely that BDNF could affect the response to MMT. Differential response to MMT could be a consequence of a reduction of brain plasticity arising from an altered expression and functionality of BDNF. From our data, we cannot infer any biological effect on BDNF protein levels. To date, the most widely reported BNDF variant that has been functionally tested is Val66Met (rs6265), which has been shown to affect intracellular trafficking and activity-dependent secretion of BDNF protein (Egan et al. 2003). Strong evidence has been reported of the role of Val66Met in substance abuse (Cheng et al. 2005; Itoh et al. 2005; Matsushita et al. 2004), but we were not able to find evidence of the effect of this single polymorphism in terms of response to MMT in our analyses. Moreover, in accordance with observed haploblock structure differences between groups, informative SNPs that define the associated haplotype are located in the 5 0 region of BDNF. Other undetermined functional or regulatory unknown variants could be carried for the associated haplotype. Promoter variants not 520 Genes, Brain and Behavior (2008) 7:

7 BDNF SNPs in opioid addiction included in this study have been associated with BDNF levels, in addition to Val66Met (Jiang et al. 2005). Furthermore, there may be an alteration of silencing mechanisms regulated by fine control of messenger RNA expression. Specific patterns of expression in different brain regions and peripheral tissues have been reported in rats (Liu et al. 2006; Pattabiraman et al. 2005) and mice (Dennis & Levitt 2005), and a complex genomic structure has been reported in the human region (Liu et al. 2005; Pruunsild et al. 2007). Liu et al. have characterized a new gene (BDNFos) in the antisense complementary chain (Liu et al. 2005, 2006). BDNFos is transcribed to produce alternatively spliced natural antisense transcripts, and its fifth exon overlaps with the coding exon of human BDNF, suggesting a role as regulatory RNA. None of the associated SNPs in our study is located in the coding exon, but the risk haplotype could carry some of these functional variants, not directly related to the expression or function of BDNF but perhaps to a regulatory effect by BDNFos. While the small sample size of our study may limit the generalizability of our results, the careful phenotypic assessment is a point of strength of the study. Results of the present exploratory study suggest involvement of BDNF as a factor to be considered in the response to MMT independently of personality traits, environmental cues, methadone dosage and the presence of medical and psychiatric comorbidity. Moreover, taking into account preclinical and clinical studies (Graham et al. 2007; Williamson et al. 2007), the role of BDNF and cocaine use in MMT response has yet to be determined. Future studies should confirm our results in a larger sample and in addition should account for pharmacokinetic factors that influence the response to methadone treatment. References Akbarian, S., Rios, M., Liu, R.J., Gold, S.J., Fong, H.F., Zeiler, S., Coppola, V., Tessarollo, L., Jones, K.R., Nestler, E.J., Aghajanian, G.K. & Jaenisch, R. (2002) Brain-derived neurotrophic factor is essential for opiate-induced plasticity of noradrenergic neurons. J Neurosci 22, Amato, L., Davoli, M., Perucci, C.A., Ferri, M., Faggiano, F. & Mattick, R.P. (2005) An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 28, Anderson, K.D., Alderson, R.F., Altar, C.A., DiStefano, P.S., Corcoran, T.L., Lindsay, R.M. & Wiegand, S.J. (1995) Differential distribution of exogenous BDNF, NGF, and NT-3 in the brain corresponds to the relative abundance and distribution of high-affinity and low-affinity neurotrophin receptors. J Comp Neurol 357, Barratt, D.T., Coller, J.K. & Somogyi, A.A. (2006) Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. Am J Med Genet B Neuropsychiatr Genet 141, Barrett, J.C., Fry, B., Maller, J. & Daly, M.J. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, Beuten, J., Ma, J.Z., Payne, T.J., Dupont, R.T., Quezada, P., Huang, W., Crews, K.M. & Li, M.D. (2005) Significant association of BDNF haplotypes in European-American male smokers but not in European-American female or African-American smokers. Am J Med Genet B Neuropsychiatr Genet 139, Brooner, R.K., King, V.L., Kidorf, M., Schmidt, C.W. Jr & Bigelow, G.E. (1997) Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 54, Cacciola, J.S., Alterman, A.I., Rutherford, M.J., McKay, J.R. & Mulvaney, F.D. (2001) The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend 61, Cloninger, C.R., Svrakic, D.M. & Przybeck, T.R. (1993) A psychobiological model of temperament and character. Arch Gen Psychiatry 50, Cloninger, C.R., Przybeck, T.R., Svrakic, D.M. & Wetzel, R.D. (1994) The Temperament and Character Inventory (TCI): a guide to its development and use. Center for Psychobiology of Personality, St Louis, MI. Crettol, S., Deglon, J.J., Besson, J., Croquette-Krokar, M., Hammig, R., Gothuey, I., Monnat, M. & Eap, C.B. (2006) ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80, Chao, M.V. (2003) Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 4, Cheng, C.Y., Hong, C.J., Yu, Y.W., Chen, T.J., Wu, H.C. & Tsai, S.J. (2005) Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Res Mol Brain Res 140, Dennis, K.E. & Levitt, P. (2005) Regional expression of brain derived neurotrophic factor (BDNF) is correlated with dynamic patterns of promoter methylation in the developing mouse forebrain. Brain Res Mol Brain Res 140, 1 9. Ebstein, R.P. (2006) The molecular genetic architecture of human personality: beyond self-report questionnaires. Mol Psychiatry 11, Egan, M.F., Kojima, M., Callicott, J.H., Goldberg, T.E., Kolachana, B.S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., Lu, B. & Weinberger, D.R. (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112, Gabriel, S.B., Schaffner, S.F., Nguyen, H., Moore, J.M., Roy, J., Blumenstiel, B., Higgins, J., DeFelice, M., Lochner, A., Faggart, M., Liu-Cordero, S.N., Rotimi, C., Adeyemo, A., Cooper, R., Ward, R., Lander, E.S., Daly, M.J. & Altshuler, D. (2002) The structure of haplotype blocks in the human genome. Science 296, GAO. (1990) Methadone maintenance: some treatment programs are not effective; greater Federal oversights needed. United States General Accounting Office, Washington, DC (GAO/HRD ). Gerra, G., Garofano, L., Castaldini, L., Rovetto, F., Zaimovic, A., Moi, G., Bussandri, M., Branchi, B., Brambilla, F., Friso, G. & Donnini, C. (2005) Serotonin transporter promoter polymorphism genotype is associated with temperament, personality traits and illegal drugs use among adolescents. J Neural Transm 112, Gonzalez, F., Salvador, L., Martinez, J.M., Lopez, A., Ruz, I. & Guerra, D. (2002) Estudio de fiabilidad y validez de la versión española de la entrevista clínica Addiction Severity Index (ASI). In Iraurgi, I., Gonzalez, F. (eds), Instrumentos de evaluación en drogodependencias. Aula Medica Ediciones, Madrid, pp Graham, D.L., Edwards, S., Bachtell, R.K., DiLeone, R.J., Rios, M. & Self, D.W. (2007) Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse. Nat Neurosci 10, Gratacos, M., Gonzalez, J.R., Mercader, J.M., de Cid, R., Urretavizcaya, M. & Estivill, X. (2007a) Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry 61, Gratacos, M., Soria, V., Urretavizcaya, M., Gonzalez, J.R., Crespo, J.M., Bayes, M., de Cid, R., Menchon, J.M., Vallejo, J. & Estivill, X. (2007b) A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders. Pharmacogenomics J [Epub ahead of print]. Gutierrez, F., Torrens, M., Boget, T., Martin-Santos, R., Sangorrin, J., Perez, G. & Salamero, M. (2001) Psychometric properties of the Temperament and Character Inventory (TCI) questionnaire in a Spanish psychiatric population. Acta Psychiatr Scand 103, Hasin, D., Samet, S., Nunes, E., Meydan, J., Matseoane, K. & Waxman, R. (2006) Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. Am J Psychiatry 163, Genes, Brain and Behavior (2008) 7:

8 de Cid et al. Hirano, S., Sato, T., Narita, T., Kusunoki, K., Ozaki, N., Kimura, S., Takahashi, T., Sakado, K. & Uehara, T. (2002) Evaluating the state dependency of the Temperament and Character Inventory dimensions in patients with major depression: a methodological contribution. J Affect Disord 69, Itoh, K., Hashimoto, K., Shimizu, E., Sekine, Y., Ozaki, N., Inada, T., Harano, M., Iwata, N., Komiyama, T., Yamada, M., Sora, I., Nakata, K., Ujike, H. & Iyo, M. (2005) Association study between brainderived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan. Am J Med Genet B Neuropsychiatr Genet 132, Jiang, X., Xu, K., Hoberman, J., Tian, F., Marko, A.J., Waheed, J.F., Harris, C.R., Marini, A.M., Enoch, M.A. & Lipsky, R.H. (2005) BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacology 30, Kellogg, S., Melia, D., Khuri, E., Lin, A., Ho, A. & Kreek, M.J. (2006) Adolescent and young adult heroin patients: drug use and success in methadone maintenance treatment. J Addict Dis 25, Klump, K.L., Strober, M., Bulik, C.M., Thornton, L., Johnson, C., Devlin, B., Fichter, M.M., Halmi, K.A., Kaplan, A.S., Woodside, D.B., Crow, S., Mitchell, J., Rotondo, A., Keel, P.K., Berrettini, W.H., Plotnicov, K., Pollice, C., Lilenfeld, L.R. & Kaye, W.H. (2004) Personality characteristics of women before and after recovery from an eating disorder. Psychol Med 34, Kreek, M.J., Nielsen, D.A., Butelman, E.R. & LaForge, K.S. (2005) Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 8, Lake, S.L., Lyon, H., Tantisira, K., Silverman, E.K., Weiss, S.T., Laird, N.M. & Schaid, D.J. (2003) Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 55, Lang, U.E., Hellweg, R. & Gallinat, J. (2004) BDNF serum concentrations in healthy volunteers are associated with depressionrelated personality traits. Neuropsychopharmacology 29, Lang, U.E., Hellweg, R., Kalus, P., Bajbouj, M., Lenzen, K.P., Sander, T., Kunz, D. & Gallinat, J. (2005) Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology (Berl) 180, Lawford, B.R., Young, R.M., Noble, E.P., Sargent, J., Rowell, J., Shadforth, S., Zhang, X. & Ritchie, T. (2000) The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet 96, Li, J. & Ji, L. (2005) Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity 95, Liu, Q.R., Walther, D., Drgon, T., Polesskaya, O., Lesnick, T.G., Strain, K.J., de Andrade, M., Bower, J.H., Maraganore, D.M. & Uhl, G.R. (2005) Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson s disease. Am J Med Genet B Neuropsychiatr Genet 134, Liu, Q.R., Lu, L., Zhu, X.G., Gong, J.P., Shaham, Y. & Uhl, G.R. (2006) Rodent BDNF genes, novel promoters, novel splice variants, and regulation by cocaine. Brain Res 1067, Maisonpierre, P.C., Le Beau, M.M., Espinosa, R. III, Ip, N.Y., Belluscio, L., de la Monte, S.M., Squinto, S., Furth, M.E. & Yancopoulos, G.D. (1991) Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 10, Marchesi, C., Cantoni, A., Fonto, S., Giannelli, M.R. & Maggini, C. (2006) The effect of temperament and character on response to selective serotonin reuptake inhibitors in panic disorder. Acta Psychiatr Scand 114, Matsushita, S., Kimura, M., Miyakawa, T., Yoshino, A., Murayama, M., Masaki, T. & Higuchi, S. (2004) Association study of brainderived neurotrophic factor gene polymorphism and alcoholism. Alcohol Clin Exp Res 28, McLellan, A.T., Luborsky, L., Woody, G.E. & O Brien, C.P. (1980) An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 168, Pattabiraman, P.P., Tropea, D., Chiaruttini, C., Tongiorgi, E., Cattaneo, A. & Domenici, L. (2005) Neuronal activity regulates the developmental expression and subcellular localization of cortical BDNF mrna isoforms in vivo. Mol Cell Neurosci 28, Pruunsild, P., Kazantseva, A., Aid, T., Palm, K. & Timmusk, T. (2007) Dissecting the human BDNF locus: bidirectional transcription, complex splicing, and multiple promoters. Genomics 90, Rybakowski, J.K., Suwalska, A., Skibinska, M., Szczepankiewicz, A., Leszczynska-Rodziewicz, A., Permoda, A., Czerski, P.M. & Hauser, J. (2005) Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 38, Seroogy, K.B., Lundgren, K.H., Tran, T.M., Guthrie, K.M., Isackson, P.J. & Gall, C.M. (1994) Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mrnas. J Comp Neurol 342, Thoenen, H. (1995) Neurotrophins and neuronal plasticity. Science 270, Torrens, M., Serrano, D., Astals, M., Perez-Dominguez, G. & Martin- Santos, R. (2004) Diagnosing comorbid psychiatric disorders in substance abusers: validity of the Spanish versions of the Psychiatric Research Interview for Substance and Mental Disorders and the Structured Clinical Interview for DSM-IV. Am J Psychiatry 161, Ward, J., Hall, W. & Mattick, R.P. (1999) Role of maintenance treatment in opioid dependence. Lancet 353, Williamson, A., Darke, S., Ross, J. & Teesson, M. (2007) The effect of baseline cocaine use on treatment outcomes for heroin dependence over 24 months: findings from the Australian Treatment Outcome Study. J Subst Abuse Treat 33, Acknowledgments We would like to thank the patients for taking part in the study and the CAS Barceloneta nursing team and Laura Diaz for their valuable help with collecting the data. We would also like to thank Marta Ribasés for accurate BDNF SNP selection and Antonio Verdejo for helpful comments. We thank Marta Pulido, MD, for editing the manuscript and editorial assistance. Financial support was received from TV3 Marató (01/810), FIS G03/005, G03/184, PI06/0940 and CIBERESP (Spanish Ministry of Health). 522 Genes, Brain and Behavior (2008) 7:

The Functional but not Nonfunctional LILRA3 Contributes to Sex Bias in Susceptibility and Severity of ACPA-Positive Rheumatoid Arthritis

The Functional but not Nonfunctional LILRA3 Contributes to Sex Bias in Susceptibility and Severity of ACPA-Positive Rheumatoid Arthritis The Functional but not Nonfunctional LILRA3 Contributes to Sex Bias in Susceptibility and Severity of ACPA-Positive Rheumatoid Arthritis Yan Du Peking University People s Hospital 100044 Beijing CHINA

More information

Risk Factors for Alcoholism among Taiwanese Aborigines

Risk Factors for Alcoholism among Taiwanese Aborigines Risk Factors for Alcoholism among Taiwanese Aborigines Introduction Like most mental disorders, Alcoholism is a complex disease involving naturenurture interplay (1). The influence from the bio-psycho-social

More information

CONTINGENCY MANAGEMENT AND ANTISOCIAL PERSONALITY DISORDER

CONTINGENCY MANAGEMENT AND ANTISOCIAL PERSONALITY DISORDER CONTINGENCY MANAGEMENT AND ANTISOCIAL PERSONALITY DISORDER Karen K. Chan 1,3, Alice Huber 1,2,3, John M. Roll 1,3, and Vikas Gulati 1,3 Friends Research Institute, Inc. 1 Long Beach Research Foundation:

More information

Association between Dopamine Gene and Alcoholism in Pategar Community of Dharwad, Karnataka

Association between Dopamine Gene and Alcoholism in Pategar Community of Dharwad, Karnataka International Journal of Scientific and Research Publications, Volume 3, Issue 10, October 2013 1 Association between Dopamine Gene and Alcoholism in Pategar Community of Dharwad, Karnataka SOMASHEKHAR

More information

Impact of Co-Occurring Psychiatric Disorders on Retention in a Methadone Maintenance Program: An 18-Month Follow-Up Study

Impact of Co-Occurring Psychiatric Disorders on Retention in a Methadone Maintenance Program: An 18-Month Follow-Up Study Int. J. Environ. Res. Public Health 009, 6, 8-83; doi:0.3390/ijerph68 OPEN ACCESS International Journal of Environmental Research and Public Health ISSN 660-460 www.mdpi.com/journal/ijerph Article Impact

More information

RECENT epidemiological studies suggest that rates and

RECENT epidemiological studies suggest that rates and 0145-6008/03/2708-1368$03.00/0 ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH Vol. 27, No. 8 August 2003 Ethnicity and Psychiatric Comorbidity Among Alcohol- Dependent Persons Who Receive Inpatient Treatment:

More information

Treatment of Prescription Opioid Dependence

Treatment of Prescription Opioid Dependence Treatment of Prescription Opioid Dependence Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse McLean Hospital, Belmont, MA Professor of Psychiatry, Harvard Medical School, Boston, MA Prescription

More information

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment: Minimum Insurance Benefits for Patients with Opioid Use Disorder By David Kan, MD and Tauheed Zaman, MD Adopted by the California Society of Addiction Medicine Committee on Opioids and the California Society

More information

Pharmacogenetics of Topiramate Treatment for Heavy Drinking

Pharmacogenetics of Topiramate Treatment for Heavy Drinking Pharmacogenetics of Topiramate Treatment for Heavy Drinking Henry R. Kranzler, M.D. Perelman School of Medicine of the University of Pennsylvania and VISN 4 MIRECC, Philadelphia VAMC kranzler@mail.med.upenn.edu

More information

Psychiatric Comorbidity in Methamphetamine-Dependent Patients

Psychiatric Comorbidity in Methamphetamine-Dependent Patients Psychiatric Comorbidity in Methamphetamine-Dependent Patients Suzette Glasner-Edwards, Ph.D. UCLA Integrated Substance Abuse Programs August11 th, 2010 Overview Comorbidity in substance users Risk factors

More information

SeattleSNPs Interactive Tutorial: Web Tools for Site Selection, Linkage Disequilibrium and Haplotype Analysis

SeattleSNPs Interactive Tutorial: Web Tools for Site Selection, Linkage Disequilibrium and Haplotype Analysis SeattleSNPs Interactive Tutorial: Web Tools for Site Selection, Linkage Disequilibrium and Haplotype Analysis Goal: This tutorial introduces several websites and tools useful for determining linkage disequilibrium

More information

YOUNG ADULTS IN DUAL DIAGNOSIS TREATMENT: COMPARISON TO OLDER ADULTS AT INTAKE AND POST-TREATMENT

YOUNG ADULTS IN DUAL DIAGNOSIS TREATMENT: COMPARISON TO OLDER ADULTS AT INTAKE AND POST-TREATMENT YOUNG ADULTS IN DUAL DIAGNOSIS TREATMENT: COMPARISON TO OLDER ADULTS AT INTAKE AND POST-TREATMENT Siobhan A. Morse, MHSA, CRC, CAI, MAC Director of Fidelity and Research Foundations Recovery Network YOUNG

More information

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years

Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957

More information

FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma

FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma FRN Research Report January 2012: Treatment Outcomes for Opiate Addiction at La Paloma Background A growing opiate abuse epidemic has highlighted the need for effective treatment options. This study documents

More information

Just the Facts: A Basic Introduction to the Science Underlying NCBI Resources

Just the Facts: A Basic Introduction to the Science Underlying NCBI Resources 1 of 8 11/7/2004 11:00 AM National Center for Biotechnology Information About NCBI NCBI at a Glance A Science Primer Human Genome Resources Model Organisms Guide Outreach and Education Databases and Tools

More information

SNPbrowser Software v3.5

SNPbrowser Software v3.5 Product Bulletin SNP Genotyping SNPbrowser Software v3.5 A Free Software Tool for the Knowledge-Driven Selection of SNP Genotyping Assays Easily visualize SNPs integrated with a physical map, linkage disequilibrium

More information

Co-Occurring Substance Use and Mental Health Disorders. Joy Chudzynski, PsyD UCLA Integrated Substance Abuse Programs

Co-Occurring Substance Use and Mental Health Disorders. Joy Chudzynski, PsyD UCLA Integrated Substance Abuse Programs Co-Occurring Substance Use and Mental Health Disorders Joy Chudzynski, PsyD UCLA Integrated Substance Abuse Programs Introduction Overview of the evolving field of Co-Occurring Disorders Addiction and

More information

California Cornflakes and Brown Sugar: The Genetic Predisposition to Heroin and Cocaine Addiction

California Cornflakes and Brown Sugar: The Genetic Predisposition to Heroin and Cocaine Addiction Genetic Predisposition to Addiction 1 Annie Smartt Biochem 118q Professor Doug Brutlag November 30 2010 California Cornflakes and Brown Sugar: The Genetic Predisposition to Heroin and Cocaine Addiction

More information

The Changing Face of Opioid Addiction:

The Changing Face of Opioid Addiction: 9th Annual Training and Educational Symposium September 6, 2012 The Changing Face of Opioid Addiction: A Review of the Research and Considerations for Care Mark Stanford, Ph.D. Santa Clara County Dept

More information

Temperament and Character Inventory R (TCI R) and Big Five Questionnaire (BFQ): convergence and divergence 1

Temperament and Character Inventory R (TCI R) and Big Five Questionnaire (BFQ): convergence and divergence 1 Psychological Reports, 2012, 110, 3, 1002-1006. Psychological Reports 2012 Temperament and Character Inventory R (TCI R) and Big Five Questionnaire (BFQ): convergence and divergence 1 Cristina Capanna,

More information

Predictors of Substance Abuse Treatment Engagement among Rural Appalachian Prescription Drug Users

Predictors of Substance Abuse Treatment Engagement among Rural Appalachian Prescription Drug Users Predictors of Substance Abuse Treatment Engagement among Rural Appalachian Prescription Drug Users Jennifer R. Havens, PhD, MPH Carrie B. Oser, PhD Carl G. Leukefeld, PhD Study Objective The objective

More information

Co occuring Antisocial Personality Disorder and Substance Use Disorder: Treatment Interventions Joleen M. Haase

Co occuring Antisocial Personality Disorder and Substance Use Disorder: Treatment Interventions Joleen M. Haase Co occuring Antisocial Personality Disorder and Substance Use Disorder: Treatment Interventions Joleen M. Haase Abstract: Substance abuse is highly prevalent among individuals with a personality disorder

More information

Alcohol Overuse and Abuse

Alcohol Overuse and Abuse Alcohol Overuse and Abuse ACLI Medical Section CME Meeting February 23, 2015 Daniel Z. Lieberman, MD Professor and Vice Chair Department of Psychiatry George Washington University Alcohol OVERVIEW Definitions

More information

Delivery of Tobacco Dependence Treatment for Tobacco Users with Mental Illness and Substance Use Disorders (MISUD)

Delivery of Tobacco Dependence Treatment for Tobacco Users with Mental Illness and Substance Use Disorders (MISUD) Delivery of Tobacco Dependence Treatment for Tobacco Users with Mental Illness and Substance Use Disorders (MISUD) Learning Objectives Upon completion of this module, you should be able to: Describe how

More information

Globally, about 9.7% of cancers in men are prostate cancers, and the risk of developing the

Globally, about 9.7% of cancers in men are prostate cancers, and the risk of developing the Chapter 5 Analysis of Prostate Cancer Association Study Data 5.1 Risk factors for Prostate Cancer Globally, about 9.7% of cancers in men are prostate cancers, and the risk of developing the disease has

More information

DrugFacts: Treatment Approaches for Drug Addiction

DrugFacts: Treatment Approaches for Drug Addiction DrugFacts: Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please

More information

A Multi-locus Genetic Risk Score for Abdominal Aortic Aneurysm

A Multi-locus Genetic Risk Score for Abdominal Aortic Aneurysm A Multi-locus Genetic Risk Score for Abdominal Aortic Aneurysm Zi Ye, 1 MD, Erin Austin, 1,2 PhD, Daniel J Schaid, 2 PhD, Iftikhar J. Kullo, 1 MD Affiliations: 1 Division of Cardiovascular Diseases and

More information

The VEdeTTE cohort study: Effectiveness of treatments for heroin addiction in retaining patients and reducing mortality

The VEdeTTE cohort study: Effectiveness of treatments for heroin addiction in retaining patients and reducing mortality The VEdeTTE cohort study: Effectiveness of treatments for heroin addiction in retaining patients and reducing mortality Federica Vigna-Taglianti www.oed.piemonte.it Piedmont Centre for Drug Addiction Epidemiology

More information

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines - 2015

ADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines - 2015 The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least

More information

Internal Medicine Residency, University of Colorado Health Sciences Center. Psychiatry Residency, University of California at San Francisco

Internal Medicine Residency, University of Colorado Health Sciences Center. Psychiatry Residency, University of California at San Francisco Internal Medicine Residency, University of Colorado Health Sciences Center Psychiatry Residency, University of California at San Francisco Addiction Psychiatry Fellowship, University of New Mexico E-mail:

More information

Addiction Neurobiology

Addiction Neurobiology Addiction Neurobiology Stephen Jurd University of Sydney Australia Richard W is sick Apology The site of pathology IF Addiction has a neurobiological basis THEN we should be able to: Define addiction AND

More information

The NJSAMS Report. Heroin Admissions to Substance Abuse Treatment in New Jersey. In Brief. New Jersey Substance Abuse Monitoring System.

The NJSAMS Report. Heroin Admissions to Substance Abuse Treatment in New Jersey. In Brief. New Jersey Substance Abuse Monitoring System. New Jersey Substance Abuse Monitoring System The NJSAMS Report May 2011 Admissions to Substance Abuse Treatment in New Jersey eroin is a semi-synthetic opioid drug derived from morphine. It has a high

More information

Lecture 6: Single nucleotide polymorphisms (SNPs) and Restriction Fragment Length Polymorphisms (RFLPs)

Lecture 6: Single nucleotide polymorphisms (SNPs) and Restriction Fragment Length Polymorphisms (RFLPs) Lecture 6: Single nucleotide polymorphisms (SNPs) and Restriction Fragment Length Polymorphisms (RFLPs) Single nucleotide polymorphisms or SNPs (pronounced "snips") are DNA sequence variations that occur

More information

Pathological Gambling and Age: Differences in personality, psychopathology, and response to treatment variables

Pathological Gambling and Age: Differences in personality, psychopathology, and response to treatment variables Addictive Behaviors 30 (2005) 383 388 Short communication Pathological Gambling and Age: Differences in personality, psychopathology, and response to treatment variables A. González-Ibáñez a, *, M. Mora

More information

Understanding Addiction: The Intersection of Biology and Psychology

Understanding Addiction: The Intersection of Biology and Psychology Understanding Addiction: The Intersection of Biology and Psychology Robert Heimer, Ph.D. Yale University School of Public Health Center for Interdisciplinary Research on AIDS New Haven, CT, USA November

More information

DSM-IV Alcohol Dependence. Alcohol and Drug Abuse. Screening for Alcohol Risk. DSM-IV Alcohol Abuse

DSM-IV Alcohol Dependence. Alcohol and Drug Abuse. Screening for Alcohol Risk. DSM-IV Alcohol Abuse DSM-IV Alcohol Dependence Alcohol and Drug Abuse David Gilder, MD Division of Mental Health Scripps Clinic Alcohol Research Center The Scripps Research Institute 1.5.11 Three or more criteria, same 12

More information

Seminar/Talk Calendar

Seminar/Talk Calendar Seminar/Talk Calendar Tuesday, February 3rd Dr. John Neumaier, Professor of Psychiatry and Pharmacology, University of Washington DREADDing Addiction Dr. Neumaier s laboratory is studying stress and addiction

More information

POWDER COCAINE: HOW THE TREATMENT SYSTEM IS RESPONDING TO A GROWING PROBLEM

POWDER COCAINE: HOW THE TREATMENT SYSTEM IS RESPONDING TO A GROWING PROBLEM Effective treatment is available for people who have a powder-cocaine problem seven in ten of those who come into treatment either stop using or reduce their use substantially within six months POWDER

More information

NEXT STEPS: TREATING TOBACCO AND CREATING HEALTHY MENTAL HEALTH/SUBSTANCE ABUSE TREATMENT FACILITY ENVIRONMENTS PART I

NEXT STEPS: TREATING TOBACCO AND CREATING HEALTHY MENTAL HEALTH/SUBSTANCE ABUSE TREATMENT FACILITY ENVIRONMENTS PART I NEXT STEPS: TREATING TOBACCO AND CREATING HEALTHY MENTAL HEALTH/SUBSTANCE ABUSE TREATMENT FACILITY ENVIRONMENTS PART I Stan Martin, MM Program Director CAI, TCTP Dr John R. Hughes February 19, 2014 Housekeeping

More information

The Adverse Health Effects of Cannabis

The Adverse Health Effects of Cannabis The Adverse Health Effects of Cannabis Wayne Hall National Addiction Centre Kings College London and Centre for Youth Substance Abuse Research University of Queensland Assessing the Effects of Cannabis

More information

Human Mendelian Disorders. Genetic Technology. What is Genetics? Genes are DNA 9/3/2008. Multifactorial Disorders

Human Mendelian Disorders. Genetic Technology. What is Genetics? Genes are DNA 9/3/2008. Multifactorial Disorders Human genetics: Why? Human Genetics Introduction Determine genotypic basis of variant phenotypes to facilitate: Understanding biological basis of human genetic diversity Prenatal diagnosis Predictive testing

More information

Combining Data from Different Genotyping Platforms. Gonçalo Abecasis Center for Statistical Genetics University of Michigan

Combining Data from Different Genotyping Platforms. Gonçalo Abecasis Center for Statistical Genetics University of Michigan Combining Data from Different Genotyping Platforms Gonçalo Abecasis Center for Statistical Genetics University of Michigan The Challenge Detecting small effects requires very large sample sizes Combined

More information

NEUROPHARMACOLOGY AND ADDICTION CHRISTOPHER M. JONES, PHARMD, MPH

NEUROPHARMACOLOGY AND ADDICTION CHRISTOPHER M. JONES, PHARMD, MPH NEUROPHARMACOLOGY AND ADDICTION CHRISTOPHER M. JONES, PHARMD, MPH Disclosures This presentation does not represent the views of the US Public Health Service or the US Food and Drug Administration The majority

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call the

More information

C-Reactive Protein and Diabetes: proving a negative, for a change?

C-Reactive Protein and Diabetes: proving a negative, for a change? C-Reactive Protein and Diabetes: proving a negative, for a change? Eric Brunner PhD FFPH Reader in Epidemiology and Public Health MRC Centre for Causal Analyses in Translational Epidemiology 2 March 2009

More information

Personality Disorders (PD) Summary (print version)

Personality Disorders (PD) Summary (print version) Personality Disorders (PD) Summary (print version) 1/ Definition A Personality Disorder is an abnormal, extreme and persistent variation from the normal (statistical) range of one or more personality attributes

More information

Assessment and Diagnosis of DSM-5 Substance-Related Disorders

Assessment and Diagnosis of DSM-5 Substance-Related Disorders Assessment and Diagnosis of DSM-5 Substance-Related Disorders Jason H. King, PhD (listed on p. 914 of DSM-5 as a Collaborative Investigator) j.king@lecutah.com or 801-404-8733 www.lecutah.com D I S C L

More information

HLA data analysis in anthropology: basic theory and practice

HLA data analysis in anthropology: basic theory and practice HLA data analysis in anthropology: basic theory and practice Alicia Sanchez-Mazas and José Manuel Nunes Laboratory of Anthropology, Genetics and Peopling history (AGP), Department of Anthropology and Ecology,

More information

Hepatitis C Virus Direct-Acting Antivirals Prior Authorization Request Form

Hepatitis C Virus Direct-Acting Antivirals Prior Authorization Request Form Hepatitis C Virus Direct-Acting Antivirals Prior Authorization Request Form For assistance, please call 1-855-552-6028 or fax completed form to 570-271-5610. Medical documentation may be requested. This

More information

Office-based Treatment of Opioid Dependence with Buprenorphine

Office-based Treatment of Opioid Dependence with Buprenorphine Office-based Treatment of Opioid Dependence with Buprenorphine David A. Fiellin, M.D Professor of Medicine, Investigative Medicine and Public Health Yale University School of Medicine Dr. Fiellin s Disclosures

More information

Special Populations in Alcoholics Anonymous. J. Scott Tonigan, Ph.D., Gerard J. Connors, Ph.D., and William R. Miller, Ph.D.

Special Populations in Alcoholics Anonymous. J. Scott Tonigan, Ph.D., Gerard J. Connors, Ph.D., and William R. Miller, Ph.D. Special Populations in Alcoholics Anonymous J. Scott Tonigan, Ph.D., Gerard J. Connors, Ph.D., and William R. Miller, Ph.D. The vast majority of Alcoholics Anonymous (AA) members in the United States are

More information

Contents. Acknowledgements List of abbreviations. xix xxi

Contents. Acknowledgements List of abbreviations. xix xxi Table of Preface Acknowledgements List of abbreviations page xv xix xxi Chapter 1. Introduction 1 1.1. Introduction 1 1.1.1. Neuroethics: the promises and perils of neuroscience research 4 1.2. Addiction

More information

The Influence of Comorbid Major Depression and Substance Use Disorders on Alcohol and Drug Treatment: Results of a National Survey

The Influence of Comorbid Major Depression and Substance Use Disorders on Alcohol and Drug Treatment: Results of a National Survey The Influence of Comorbid Major Depression and Substance Use Disorders on Alcohol and Drug Treatment: Results of a National Survey Bridget F. Grant INTRODUCTION The co-occurrence of alcohol use disorders,

More information

The use of alcohol and drugs and HIV treatment compliance in Brazil

The use of alcohol and drugs and HIV treatment compliance in Brazil The use of alcohol and drugs and HIV treatment compliance in Brazil André Malbergier, MD, PhD Hospital das Clínicas Medical School University of São Paulo Brasil The Casa da AIDS offers specialized integral

More information

Non-replication of interaction between cannabis use and trauma in predicting psychosis. & Jim van Os

Non-replication of interaction between cannabis use and trauma in predicting psychosis. & Jim van Os Non-replication of interaction between cannabis use and trauma in predicting psychosis Rebecca Kuepper 1, Cécile Henquet 1, 3, Roselind Lieb 4, 5, Hans-Ulrich Wittchen 4, 6 1, 2* & Jim van Os 1 Department

More information

DnaSP, DNA polymorphism analyses by the coalescent and other methods.

DnaSP, DNA polymorphism analyses by the coalescent and other methods. DnaSP, DNA polymorphism analyses by the coalescent and other methods. Author affiliation: Julio Rozas 1, *, Juan C. Sánchez-DelBarrio 2,3, Xavier Messeguer 2 and Ricardo Rozas 1 1 Departament de Genètica,

More information

HHS Public Access Author manuscript J Clin Psychiatry. Author manuscript; available in PMC 2015 August 05.

HHS Public Access Author manuscript J Clin Psychiatry. Author manuscript; available in PMC 2015 August 05. Association of the rs2242446 polymorphism in the norepinephrine transporter gene SLC6A2 and anxious arousal symptoms of posttraumatic stress disorder Robert H. Pietrzak, Ph.D., M.P.H. a,b, Jennifer A.

More information

A PROSPECTIVE EVALUATION OF THE RELATIONSHIP BETWEEN REASONS FOR DRINKING AND DSM-IV ALCOHOL-USE DISORDERS

A PROSPECTIVE EVALUATION OF THE RELATIONSHIP BETWEEN REASONS FOR DRINKING AND DSM-IV ALCOHOL-USE DISORDERS Pergamon Addictive Behaviors, Vol. 23, No. 1, pp. 41 46, 1998 Copyright 1998 Elsevier Science Ltd Printed in the USA. All rights reserved 0306-4603/98 $19.00.00 PII S0306-4603(97)00015-4 A PROSPECTIVE

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call 1-800-662-HELP(4357)

More information

Background & Significance

Background & Significance The Impact Of A Structured Opioid Renewal Clinic On Aberrant Drug Behavior Outcomes At A Northeastern VA Medical Center Salimah H. Meghani, PhD, MBE, CRNP Assistant Professor, University of Pennsylvania

More information

Medication-Assisted Addiction Treatment

Medication-Assisted Addiction Treatment Medication-Assisted Addiction Treatment Molly Carney, Ph.D., M.B.A. Executive Director Evergreen Treatment Services Seattle, WA What is MAT? MAT is the use of medications, in combination with counseling

More information

Addressing Substance and Alcohol Use Prior to HCV Treatment

Addressing Substance and Alcohol Use Prior to HCV Treatment Addressing Substance and Alcohol Use Prior to HCV Treatment Glenn J. Treisman, MD, PhD The Johns Hopkins University School of Medicine Baltimore, Maryland Disclosure Information Dr Treisman has no relevant

More information

SeqScape Software Version 2.5 Comprehensive Analysis Solution for Resequencing Applications

SeqScape Software Version 2.5 Comprehensive Analysis Solution for Resequencing Applications Product Bulletin Sequencing Software SeqScape Software Version 2.5 Comprehensive Analysis Solution for Resequencing Applications Comprehensive reference sequence handling Helps interpret the role of each

More information

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Considerations in Medication Assisted Treatment of Opiate Dependence Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT Disclosures Speaker Panels- None Grant recipient - SAMHSA

More information

Identifying High and Low Risk Practice Areas and Drugs of Choice of Chemically Dependent Nurses

Identifying High and Low Risk Practice Areas and Drugs of Choice of Chemically Dependent Nurses Identifying High and Low Risk Practice Areas and Drugs of Choice of Chemically Dependent Nurses Jessica Furstenberg, Kawa Cheong, Ashley Brill, Angela M. McNelis, PhD, RN, Sara Horton-Deutsch, PhD, RN,

More information

With Depression Without Depression 8.0% 1.8% Alcohol Disorder Drug Disorder Alcohol or Drug Disorder

With Depression Without Depression 8.0% 1.8% Alcohol Disorder Drug Disorder Alcohol or Drug Disorder Minnesota Adults with Co-Occurring Substance Use and Mental Health Disorders By Eunkyung Park, Ph.D. Performance Measurement and Quality Improvement May 2006 In Brief Approximately 16% of Minnesota adults

More information

Personality Disorders

Personality Disorders Personality Disorders Chapter 11 Personality Disorders: An Overview The Nature of Personality and Personality Disorders Enduring and relatively stable predispositions (i.e., ways of relating and thinking)

More information

Frequent headache is defined as headaches 15 days/month and daily. Course of Frequent/Daily Headache in the General Population and in Medical Practice

Frequent headache is defined as headaches 15 days/month and daily. Course of Frequent/Daily Headache in the General Population and in Medical Practice DISEASE STATE REVIEW Course of Frequent/Daily Headache in the General Population and in Medical Practice Egilius L.H. Spierings, MD, PhD, Willem K.P. Mutsaerts, MSc Department of Neurology, Brigham and

More information

The relationship among alcohol use, related problems, and symptoms of psychological distress: Gender as a moderator in a college sample

The relationship among alcohol use, related problems, and symptoms of psychological distress: Gender as a moderator in a college sample Addictive Behaviors 29 (2004) 843 848 The relationship among alcohol use, related problems, and symptoms of psychological distress: Gender as a moderator in a college sample Irene Markman Geisner*, Mary

More information

Treatment Approaches for Drug Addiction

Treatment Approaches for Drug Addiction Treatment Approaches for Drug Addiction [NOTE: This is a fact sheet covering research findings on effective treatment approaches for drug abuse and addiction. If you are seeking treatment, please call

More information

Suicide Assessment in the Elderly Geriatric Psychiatric for the Primary Care Provider 2008

Suicide Assessment in the Elderly Geriatric Psychiatric for the Primary Care Provider 2008 Suicide Assessment in the Elderly Geriatric Psychiatric for the Primary Care Provider 2008 Lisa M. Brown, Ph.D. Aging and Mental Health Louis de la Parte Florida Mental Health Institute University of South

More information

Unit 4: Personality, Psychological Disorders, and Treatment

Unit 4: Personality, Psychological Disorders, and Treatment Unit 4: Personality, Psychological Disorders, and Treatment Learning Objective 1 (pp. 131-132): Personality, The Trait Approach 1. How do psychologists generally view personality? 2. What is the focus

More information

Bildgebung und Genetik

Bildgebung und Genetik DGPPN, 23.11.2012 Bildgebung und Genetik Andreas Meyer-Lindenberg Zentralinstitut für Seelische Gesundheit, Mannheim Complex path from gene to behavior Meyer-Lindenberg and Weinberger, Nature Neuroscience

More information

Major Depressive Disorder: Stage 1 Genomewide Association in Population-Based Samples.

Major Depressive Disorder: Stage 1 Genomewide Association in Population-Based Samples. Major Depressive Disorder: Stage 1 Genomewide Association in Population-Based Samples. Patrick Sullivan 1, Danyu Lin 1, Jung-Ying Tzeng 4, Gonneke Willemsen 2, Eco de Geus 2, Dorret Boomsma 2 Jan Smit

More information

Executive Summary. 1. What is the temporal relationship between problem gambling and other co-occurring disorders?

Executive Summary. 1. What is the temporal relationship between problem gambling and other co-occurring disorders? Executive Summary The issue of ascertaining the temporal relationship between problem gambling and cooccurring disorders is an important one. By understanding the connection between problem gambling and

More information

SICKLE CELL ANEMIA & THE HEMOGLOBIN GENE TEACHER S GUIDE

SICKLE CELL ANEMIA & THE HEMOGLOBIN GENE TEACHER S GUIDE AP Biology Date SICKLE CELL ANEMIA & THE HEMOGLOBIN GENE TEACHER S GUIDE LEARNING OBJECTIVES Students will gain an appreciation of the physical effects of sickle cell anemia, its prevalence in the population,

More information

STEP-BD. Methods. STEP-BD Baseline Findings. Lessons from STEP-BD for the Treatment of Bipolar Disorder

STEP-BD. Methods. STEP-BD Baseline Findings. Lessons from STEP-BD for the Treatment of Bipolar Disorder Lessons from for the Treatment of Bipolar Disorder Andrew A. Nierenberg, MD Massachusetts General Hospital Harvard Medical School Systematic Treatment Enhancement Program for Bipolar Disorder www.stepbd.org

More information

The role of aldehyde dehydrogenase-1 (ALDH1A1) polymorphisms in harmful alcohol consumption in a Finnish population

The role of aldehyde dehydrogenase-1 (ALDH1A1) polymorphisms in harmful alcohol consumption in a Finnish population PRIMARY RESARCH The role of aldehyde dehydrogenase-1 (ALDH1A1) polymorphisms in harmful alcohol consumption in a Finnish population Penelope A. Lind, 1 C.J. Peter Eriksson 2* and Kirk C. Wilhelmsen 3 1

More information

Treatment Research Institute 600 Public Ledger Building, 150 S. Independence Mall West Philadelphia, PA 19106-3475 (800 )238-2433

Treatment Research Institute 600 Public Ledger Building, 150 S. Independence Mall West Philadelphia, PA 19106-3475 (800 )238-2433 From The University of Pennsylvania/Veterans Administration Center for Studies of Addiction Supported by Grants from the National Institute of Drug Abuse(project DA 02254) and the Veterans Administration

More information

The Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction

The Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction The Results of a Pilot of Vivitrol: A Medication Assisted Treatment for Alcohol and Opioid Addiction James H. Barger, MD SAPC Medical Director and Science Officer Desiree A. Crevecoeur-MacPhail, Ph.D.

More information

CODES FOR PHARMACY ONLINE CLAIMS PROCESSING

CODES FOR PHARMACY ONLINE CLAIMS PROCESSING S FOR PHARMACY ONLINE CLAIMS PROCESSING The following is a list of error and warning codes that may appear when processing claims on the online system. The error codes are bolded. CODE AA AB AI AR CB CD

More information

12 Steps to Changing Neuropathways. Julie Denton

12 Steps to Changing Neuropathways. Julie Denton 12 Steps to Changing Neuropathways Julie Denton Review the neurobiology of the brain Understand the basics of neurological damage to the brain from addiction Understand how medications and psychotherapy

More information

Evidence-Based Treatment for Opiate-Dependent Clients: Availability, Variation, and Organizational Correlates

Evidence-Based Treatment for Opiate-Dependent Clients: Availability, Variation, and Organizational Correlates The American Journal of Drug and Alcohol Abuse, 32: 569 576, 2006 Copyright Q Informa Healthcare ISSN: 0095-2990 print/1097-9891 online DOI: 10.1080/00952990600920417 Evidence-Based Treatment for Opiate-Dependent

More information

Name Date Period. 2. When a molecule of double-stranded DNA undergoes replication, it results in

Name Date Period. 2. When a molecule of double-stranded DNA undergoes replication, it results in DNA, RNA, Protein Synthesis Keystone 1. During the process shown above, the two strands of one DNA molecule are unwound. Then, DNA polymerases add complementary nucleotides to each strand which results

More information

Algorithms in Computational Biology (236522) spring 2007 Lecture #1

Algorithms in Computational Biology (236522) spring 2007 Lecture #1 Algorithms in Computational Biology (236522) spring 2007 Lecture #1 Lecturer: Shlomo Moran, Taub 639, tel 4363 Office hours: Tuesday 11:00-12:00/by appointment TA: Ilan Gronau, Taub 700, tel 4894 Office

More information

TEEN MARIJUANA USE WORSENS DEPRESSION

TEEN MARIJUANA USE WORSENS DEPRESSION TEEN MARIJUANA USE WORSENS DEPRESSION An Analysis of Recent Data Shows Self-Medicating Could Actually Make Things Worse Millions of American teens* report experiencing weeks of hopelessness and loss of

More information

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Cardwell C Nuckols, PhD cnuckols@elitecorp1.com Cardwell C. Nuckols, PhD www.cnuckols.com SECTION I-BASICS DSM-5 Includes

More information

Observational study of the long-term efficacy of ibogaine-assisted therapy in participants with opioid addiction STUDY PROTOCOL

Observational study of the long-term efficacy of ibogaine-assisted therapy in participants with opioid addiction STUDY PROTOCOL Observational study of the long-term efficacy of ibogaine-assisted therapy in participants with opioid addiction Purpose and Objectives STUDY PROTOCOL This research is an investigator-sponsored observational

More information

University of Michigan Dearborn Graduate Psychology Assessment Program

University of Michigan Dearborn Graduate Psychology Assessment Program University of Michigan Dearborn Graduate Psychology Assessment Program Graduate Clinical Health Psychology Program Goals 1 Psychotherapy Skills Acquisition: To train students in the skills and knowledge

More information

Treatment of opioid use disorders

Treatment of opioid use disorders Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence

More information

GAIN and DSM. Presentation Objectives. Using the GAIN Diagnostically

GAIN and DSM. Presentation Objectives. Using the GAIN Diagnostically GAIN and DSM GAIN National Clinical Training Team 2011 Version 2 Materials Presentation Objectives Understand which DSM diagnoses are generated by GAIN ABS for the GAIN reports and which ones must be added

More information

FACTORS AFFECTING TREATMENT OUTCOMES

FACTORS AFFECTING TREATMENT OUTCOMES FACTORS AFFECTING TREATMENT OUTCOMES FOR PATIENTS UNDERGOING METHADONE TREATMENT FOR OPIOID ADDICTION A FOCUS ON SEX HORMONES AND CHRONIC PAIN Monica Bawor, BSc, PhD Student Psychiatry & Behavioral Neurosciences,

More information

Causes of Alcohol Abuse and Alcoholism: Biological/Biochemical Perspectives

Causes of Alcohol Abuse and Alcoholism: Biological/Biochemical Perspectives Causes of Alcohol Abuse and Alcoholism: Biological/Biochemical Perspectives Neurobehavioral Aspects of Alcohol Consumption Source: Eighth Special Report to the U.S. Congress on Alcohol and Health Secretary

More information

BOARD OF PHARMACY SPECIALITIES 2215 Constitution Avenue, NW Washington, DC 20037-2985 202-429-7591 FAX 202-429-6304 bps@aphanet.org www.bpsweb.

BOARD OF PHARMACY SPECIALITIES 2215 Constitution Avenue, NW Washington, DC 20037-2985 202-429-7591 FAX 202-429-6304 bps@aphanet.org www.bpsweb. BOARD OF PHARMACY SPECIALITIES 2215 Constitution Avenue, NW Washington, DC 20037-2985 202-429-7591 FAX 202-429-6304 bps@aphanet.org www.bpsweb.org Content Outline for the PSYCHIATRIC PHARMACY SPECIALTY

More information

Are differences in methylation in cord blood DNA associated with prenatal exposure to alcohol?

Are differences in methylation in cord blood DNA associated with prenatal exposure to alcohol? Are differences in methylation in cord blood DNA associated with prenatal exposure to alcohol? Luisa Zuccolo l.zuccolo@bristol.ac.uk MRC IEU, School of Social and Community Medicine Outline Background

More information

This report was prepared by the staff of the Health Survey Program:

This report was prepared by the staff of the Health Survey Program: Massachusetts Department of Public Health Health Survey Program Center for Health Information, Statistics, Research, and Evaluation Alcohol Use, Illicit Drug Use, and Gambling in Massachusetts, 22 Supplement

More information

Nuevas tecnologías basadas en biomarcadores para oncología

Nuevas tecnologías basadas en biomarcadores para oncología Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS

More information

In Brief UTAH. Adolescent Behavioral Health. A Short Report from the Office of Applied Studies

In Brief UTAH. Adolescent Behavioral Health. A Short Report from the Office of Applied Studies UTAH Adolescent Behavioral Health In Brief A Short Report from the Office of Applied Studies Adolescence (12 to 17 years) is a critical and vulnerable stage of human development, during which males and

More information

Medical marijuana for pain and anxiety: A primer for methadone physicians. Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015

Medical marijuana for pain and anxiety: A primer for methadone physicians. Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015 Medical marijuana for pain and anxiety: A primer for methadone physicians Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015 Conflict of interest statement No conflict of interest to

More information

SUBSTANCE ABUSE OUTPATIENT SERVICES

SUBSTANCE ABUSE OUTPATIENT SERVICES SUBSTANCE ABUSE OUTPATIENT SERVICES A. DEFINITION: Substance Abuse Outpatient is the provision of medical or other treatment and/or counseling to address substance abuse problems (i.e., alcohol and/or

More information